ClinicalTrials.gg
CompletedNCT03176134Updated Jul 31, 2025Results posted

A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)

A Phase 3 interventional study of Tedizolid phosphate and Comparator in Acute Bacterial Skin and Skin Structure Infections, sponsored by Merck Sharp & Dohme LLC. Completed at 58 sites in 14 countries. Open to participants aged 1 Day to 11 Years. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
1 Day to 11 Years
Sex
All
01

Study summary

This study will evaluate the safety, tolerability, and efficacy of tedizolid phosphate (MK-1986) compared with comparator antibacterial agent in participants from birth to less than 12 years of age with acute bacterial skin and skin structure infections (ABSSSI).

Read the detailed description

Participants will be randomized (3:1) to receive tedizolid phosphate at a weight-based dose ≤200 mg/day, intravenous (IV) and/or oral suspension for 6 to 10 days, or comparator IV and/or oral per local standard of care for 10 to 14 days. The switch from IV to oral administration can be made at any time based on 1) no worsening of the primary skin lesion, 2) last temperature \<37.7 °C, and 3) primary acute bacterial skin and skin structure infection (ABSSSI) site has not worsened and at least 1 site has improved from Baseline. The potential 4-day treatment extension will be based on clinical need as judged by the investigator, considering the following criteria: 1) ≥40% reduction in primary lesion size, 2) reduction in pain, and 3) no new signs and symptoms and no complications attributable to ABSSSI compared with Baseline.

02

Conditions studied

  • Acute Bacterial Skin and Skin Structure Infections
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Day to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a parent/legally acceptable representative who is able to give documented
  • Has acute bacterial skin and skin structure infections (ABSSSI), defined as ≥1 of the following: 1) cellulitis/erysipelas, 2) major cutaneous abscess, or 3) wound infection
  • Local symptoms of ABSSSI that started within 14 days before study start
  • Suspected or documented Gram-positive bacterial infection

Exclusion criteria

Exclusion Criteria:

  • Uncomplicated skin and skin structure infection
  • ABSSSI due to or associated with disallowed etiology per protocol
  • Received antibacterial therapy for treatment of the current episode of ABSSSI except 1) \<48 hours of antibacterial therapy with a short-acting antibacterial drug, or 2) response is considered to be failure (no improvement in signs and symptoms) after at least 48 hours of therapy
  • Known bacteremia, severe sepsis, or septic shock
  • Significant or life-threatening condition, disease, or organ system condition
  • Recent history of opportunistic infections where the underlying cause of the infection is still active, or is suspected to be at risk of opportunistic infection with unusual pathogens
  • Received or is receiving treatment for active tuberculosis within 1 month of study start
  • Known or suspected severe neutropenia
  • (HIV) positive and has Cluster of Differentiation (CD) 4 cell count \<15% (HIV testing is not required for eligibility)
  • Renal impairment that requires renal filtration
  • Severe hepatic impairment
  • Cardiac or (ECG) finding that would limit participation in the study
  • Received an medicinal product (not approved) within 30 days before study start
  • Investigational device present or removed within 30 days before study start
  • Previously treated with tedizolid phosphate
  • , including to tedizolid phosphate, other oxazolidinones, or any component in the formulation
  • Contraindication, including hypersensitivity to all available comparator drugs
  • Wound infection and history of hypersensitivity to aztreonam adjunctive therapy or metronidazole adjunctive therapy, if adjunctive therapy is required
  • Needs oral administration of methotrexate, topotecan, irinotecan, or rosuvastatin, during administration of oral study drug (administration during the follow-up period, ie, after the end of treatment (EOT) visit, is allowed, as is administration during treatment with IV drug)
  • Female who is pregnant or nursing or is of and not abstinent; or male who is not abstinent
  • Use of monoamine oxidase inhibitors, tricyclic antidepressants, buspirone, selective serotonin reuptake inhibitors, or serotonin 5-hydroxytryptamine receptor agonists (triptans)
  • Identified as having used illicit drugs (urine drug screening not required for entry)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Cohort 1: Tedizolid phosphate 6 to <12 Years

    Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to \<50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to \<30 kg), by IV and/or oral suspension for 6 to 10 days.

    Drug: Tedizolid phosphate

  • Active comparator
    Cohort 1: Comparator 6 to <12 Years

    Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days.

    Drug: Comparator

  • Experimental
    Cohort 2: Tedizolid phosphate 2 to <6 Years

    Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to \<50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to \<30 kg), by IV and/or oral suspension for 6 to 10 days.

    Drug: Tedizolid phosphate

  • Active comparator
    Cohort 2: Comparator 2 to <6 Years

    Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days.

    Drug: Comparator

  • Experimental
    Cohort 3: Tedizolid phosphate 28 Days to <2 Years

    Participants will receive tedizolid phosphate once-daily single 200-mg dose (body weight ≥50 kg) or twice-daily 2-mg/kg doses (body weight 30 kg to \<50 kg); or twice-daily 2.5-mg/kg doses (body weight 3.2 kg to \<30 kg), by IV and/or oral suspension for 6 to 10 days.

    Drug: Tedizolid phosphate

  • Active comparator
    Cohort 3: Comparator 28 Days to <2 Years

    Participants will receive comparator IV and/or oral per local standard of care for 10 to 14 days.

    Drug: Comparator

  • Experimental
    Cohort 4: Tedizolid phosphate Birth to <28 Days Term and Preterm Neonates

    Participants will receive tedizolid phosphate ≤200 mg daily dose, IV and/or oral suspension for 6 to 10 days. Exact mg/kg dose is to be determined based on results of another study (NCT03217565) covering the age range.

    Drug: Tedizolid phosphate

  • Active comparator
    Cohort 4: Comparator Birth to <28 Days Term and Preterm Neonates

    Participants will receive comparator IV and/or oral per local standard of care for 10 to14 days.

    Drug: Comparator

Interventions

  • Tedizolid phosphate IV solution or oral suspension

    Also known as: MK-1986, TR-701 FA

  • DrugComparator

    Vancomycin IV, linezolid IV or oral (outside European Union only), clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported.

    Time frame: Up to approximately 35 days

  2. Number of Participants Who Discontinued Study Treatment Due to an AE

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported. The number of participants who discontinued study treatment due to an AE were reported.

    Time frame: Up to approximately day 15

  3. Number of Participants With Hematopoietic Cytopenias

    Hematopoietic cytopenia is a condition where there is a lower-than-normal amount of one or multiple kinds of blood cells. A standardized Medical Dictionary for Regulatory Activities (MedDRA) query for hematopoietic cytopenia was conducted. The number of participants with a hematopoietic cytopenia were reported.

    Time frame: Up to approximately 35 days

Secondary outcomes

  1. Percentage of Participants With Clinical Response (CR) Per Investigator Assessment

    CR was defined as clinical success, failure or indeterminate as per investigator assessment. Success was all of the following: resolution/near resolution of most disease-specific signs \& symptoms, absence/near resolution of regional/systemic signs of infection if present at baseline (BL) \& no new signs, symptoms, or complications, so, no further antibiotic therapy required. Failure was any of the following: requires additional antibiotic therapy, unplanned major surgical intervention required due to study drug failure, developed osteomyelitis after BL, persistent gram+ bacteremia, treatment emergent adverse event (TEAE) leading to study drug discontinuation \& required additional antibiotic therapy to treat infection or death within 28 days of first infusion. Indeterminate was no efficacy data available. Per protocol, percentage of participants with CR for Cohorts 1, 2 \& 3 \& all cohorts together were reported, \& failure \& indeterminate responses were pooled.

    Time frame: Up to approximately 25 days

  2. Percentage of Clinically Evaluable (CE) Participants With CR Per Investigator Assessment

    CR was defined as clinical success, failure or indeterminate as per investigator assessment. Success was all of the following: resolution/near resolution of most disease-specific signs \& symptoms, absence/near resolution of regional/systemic signs of infection if present at BL \& no new signs, symptoms, or complications, so, no further antibiotic therapy required. Failure was any of the following: requires additional antibiotic therapy, unplanned major surgical intervention required due to study drug failure, developed osteomyelitis after BL, persistent gram+ bacteremia, treatment emergent adverse event leading to study drug discontinuation \& required additional antibiotic therapy to treat infection or death within 28 days of first infusion. Indeterminate was no efficacy data available. Per protocol, percentage of participants with CR for Cohorts 1, 2 \& 3 and all cohorts together were reported, \& failure \& indeterminate responses were pooled.

    Time frame: Up to approximately 25 days

07

Results

Posted Jul 3, 2024

Participant flow

Participant flow — Overall Study
MilestoneCohort 1: Tedizolid Phosphate 6 to <12 YearsCohort 1: Comparator 6 to <12 YearsCohort 2: Tedizolid Phosphate 2 to <6 YearsCohort 2: Comparator 2 to <6 YearsCohort 3: Tedizolid Phosphate 28 Days to <2 YearsCohort 3: Comparator 28 Days to <2 YearsCohort 4: Tedizolid Phosphate Birth to <28 Days Term and Preterm NeonatesCohort 4: Comparator Birth to <28 Days Term and Preterm Neonates
Started441516515500
Completed421314515500
Not completed22200000
Withdrew: Lost to follow-up02000000
Withdrew: Withdrawal by parent/guardian20200000

Outcome measures

PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported.

Time frame:
Up to approximately 35 days
Reported as:
Count of participants · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsCohort 1: Tedizolid Phosphate 6 to <12 YearsCohort 1: Comparator 6 to <12 YearsCohort 2: Tedizolid Phosphate 2 to <6 YearsCohort 2: Comparator 2 to <6 YearsCohort 3: Tedizolid Phosphate 28 Days to <2 YearsCohort 3: Comparator 28 Days to <2 Years
Number of Participants Who Experienced an Adverse Event (AE)727272
PrimaryNumber of Participants Who Discontinued Study Treatment Due to an AE

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Number of participants who experienced an AE were reported. The number of participants who discontinued study treatment due to an AE were reported.

Time frame:
Up to approximately day 15
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Treatment Due to an AE
ParticipantsCohort 1: Tedizolid Phosphate 6 to <12 YearsCohort 1: Comparator 6 to <12 YearsCohort 2: Tedizolid Phosphate 2 to <6 YearsCohort 2: Comparator 2 to <6 YearsCohort 3: Tedizolid Phosphate 28 Days to <2 YearsCohort 3: Comparator 28 Days to <2 Years
Number of Participants Who Discontinued Study Treatment Due to an AE000000
PrimaryNumber of Participants With Hematopoietic Cytopenias

Hematopoietic cytopenia is a condition where there is a lower-than-normal amount of one or multiple kinds of blood cells. A standardized Medical Dictionary for Regulatory Activities (MedDRA) query for hematopoietic cytopenia was conducted. The number of participants with a hematopoietic cytopenia were reported.

Time frame:
Up to approximately 35 days
Reported as:
Count of participants · Participants
Number of Participants With Hematopoietic Cytopenias
ParticipantsCohort 1: Tedizolid Phosphate 6 to <12 YearsCohort 1: Comparator 6 to <12 YearsCohort 2: Tedizolid Phosphate 2 to <6 YearsCohort 2: Comparator 2 to <6 YearsCohort 3: Tedizolid Phosphate 28 Days to <2 YearsCohort 3: Comparator 28 Days to <2 Years
Number of Participants With Hematopoietic Cytopenias001010
SecondaryPercentage of Participants With Clinical Response (CR) Per Investigator Assessment

CR was defined as clinical success, failure or indeterminate as per investigator assessment. Success was all of the following: resolution/near resolution of most disease-specific signs \& symptoms, absence/near resolution of regional/systemic signs of infection if present at baseline (BL) \& no new signs, symptoms, or complications, so, no further antibiotic therapy required. Failure was any of the following: requires additional antibiotic therapy, unplanned major surgical intervention required due to study drug failure, developed osteomyelitis after BL, persistent gram+ bacteremia, treatment emergent adverse event (TEAE) leading to study drug discontinuation \& required additional antibiotic therapy to treat infection or death within 28 days of first infusion. Indeterminate was no efficacy data available. Per protocol, percentage of participants with CR for Cohorts 1, 2 \& 3 \& all cohorts together were reported, \& failure \& indeterminate responses were pooled.

Time frame:
Up to approximately 25 days
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinical Response (CR) Per Investigator Assessment
Percentage of ParticipantsCohort 1: Tedizolid Phosphate 6 to <12 YearsCohort 1: Comparator 6 to <12 YearsCohort 2: Tedizolid Phosphate 2 to <6 YearsCohort 2: Comparator 2 to <6 YearsCohort 3: Tedizolid Phosphate 28 Days to <2 YearsCohort 3: Comparator 28 Days to <2 YearsAll Cohorts: Tedizolid PhosphateAll Cohorts: Comparator
Clinical Success93.2 (81.3 to 98.6)86.7 (59.5 to 98.3)87.5 (61.7 to 98.4)100.00 (47.8 to 100.0)100.0 (78.2 to 100.0)100.0 (47.8 to 100.0)93.3 (85.1 to 97.8)92.0 (74.0 to 99.0)
Clinical Failure or Indeterminate6.8 (1.4 to 18.7)13.3 (1.7 to 40.5)12.5 (1.6 to 38.3)0.0 (NA to NA)0.0 (NA to NA)0.0 (NA to NA)6.7 (2.2 to 14.9)8.0 (1.0 to 26.0)
Statistical analysis
  • Cohort 1: Tedizolid Phosphate 6 to <12 Years vs Cohort 1: Comparator 6 to <12 Years · Estimated difference: 6.5 · 95% CI -12.2 to 25.3The estimated difference in the clinical success rate and 2-sided 95% confidence interval (CI) were calculated using the unstratified method of Miettinen and Nurminen.
  • Cohort 2: Tedizolid Phosphate 2 to <6 Years vs Cohort 2: Comparator 2 to <6 Years · Estimated difference: -12.5 · 95% CI -28.7 to 3.7The estimated difference in the clinical success rate and 2-sided 95% CI were calculated using the unstratified method of Miettinen and Nurminen.
  • Cohort 3: Tedizolid Phosphate 28 Days to <2 Years vs Cohort 3: Comparator 28 Days to <2 Years · Estimated difference: 0.0 · 95% CI 0.0 to 0.0The estimated difference in the clinical success rate and 2-sided 95% CI were calculated using the unstratified method of Miettinen and Nurminen.
  • All Cohorts: Tedizolid Phosphate vs All Cohorts: Comparator · Estimated difference: 1.3 · 95% CI -10.7 to 13.4The estimated difference in the clinical success rate and 2-sided 95% CI were calculated using the unstratified method of Miettinen and Nurminen.
SecondaryPercentage of Clinically Evaluable (CE) Participants With CR Per Investigator Assessment

CR was defined as clinical success, failure or indeterminate as per investigator assessment. Success was all of the following: resolution/near resolution of most disease-specific signs \& symptoms, absence/near resolution of regional/systemic signs of infection if present at BL \& no new signs, symptoms, or complications, so, no further antibiotic therapy required. Failure was any of the following: requires additional antibiotic therapy, unplanned major surgical intervention required due to study drug failure, developed osteomyelitis after BL, persistent gram+ bacteremia, treatment emergent adverse event leading to study drug discontinuation \& required additional antibiotic therapy to treat infection or death within 28 days of first infusion. Indeterminate was no efficacy data available. Per protocol, percentage of participants with CR for Cohorts 1, 2 \& 3 and all cohorts together were reported, \& failure \& indeterminate responses were pooled.

Time frame:
Up to approximately 25 days
Reported as:
Number · Percentage of Participants
Percentage of Clinically Evaluable (CE) Participants With CR Per Investigator Assessment
Percentage of ParticipantsCohort 1: Tedizolid Phosphate 6 to <12 YearsCohort 1: Comparator 6 to <12 YearsCohort 2: Tedizolid Phosphate 2 to <6 YearsCohort 2: Comparator 2 to <6 YearsCohort 3: Tedizolid Phosphate 28 Days to <2 YearsCohort 3: Comparator 28 Days to <2 YearsAll Cohorts: Tedizolid PhosphateAll Cohorts: Comparator
Clinical Success100.00 (91.0 to 100.0)100.0 (75.3 to 100.0)100.0 (76.8 to 100.0)100.00 (47.8 to 100.0)100.0 (78.2 to 100.0)100.0 (47.8 to 100.0)100.00 (94.7 to 100.0)100.0 (85.2 to 100.0)
Clinical Failure or Indeterminate0.0 (NA to NA)0.0 (NA to NA)0.0 (NA to NA)0.0 (NA to NA)0.0 (NA to NA)0.0 (NA to NA)0.0 (NA to NA)0.0 (NA to NA)
Statistical analysis
  • Cohort 1: Tedizolid Phosphate 6 to <12 Years vs Cohort 1: Comparator 6 to <12 Years · Estimated difference: 0.0 · 95% CI 0.0 to 0.0The estimated difference in the clinical success rate and 2-sided 95% confidence interval (CI) were calculated using the unstratified method of Miettinen and Nurminen.
  • Cohort 2: Tedizolid Phosphate 2 to <6 Years vs Cohort 2: Comparator 2 to <6 Years · Estimated difference: 0.0 · 95% CI 0.0 to 0.0The estimated difference in the clinical success rate and 2-sided 95% CI were calculated using the unstratified method of Miettinen and Nurminen.
  • Cohort 3: Tedizolid Phosphate 28 Days to <2 Years vs Cohort 3: Comparator 28 Days to <2 Years · Estimated difference: 0.0 · 95% CI 0.0 to 0.0The estimated difference in the clinical success rate and 2-sided 95% CI were calculated using the unstratified method of Miettinen and Nurminen.
  • All Cohorts: Tedizolid Phosphate vs All Cohorts: Comparator · Estimated difference: 0.0 · 95% CI 0.0 to 0.0The estimated difference in the clinical success rate and 2-sided 95% CI were calculated using the unstratified method of Miettinen and Nurminen.

Adverse events

Collected over Up to approximately 35 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Tedizolid Phosphate 6 to <12 Years0/44 (0%)0/44 (0%)4/44 (9.1%)
Cohort 1: Comparator 6 to <12 Years0/15 (0%)0/15 (0%)2/15 (13.3%)
Cohort 2: Tedizolid Phosphate 2 to <6 Years0/16 (0%)0/16 (0%)7/16 (43.8%)
Cohort 2: Comparator 2 to <6 Years0/5 (0%)0/5 (0%)2/5 (40%)
Cohort 3: Tedizolid Phosphate 28 Days to <2 Years0/15 (0%)0/15 (0%)7/15 (46.7%)
Cohort 3: Comparator 28 Days to <2 Years0/5 (0%)0/5 (0%)2/5 (40%)
Most frequent other events
Showing 10 of 36
Most frequent other events
EventCohort 1: Tedizolid Phosphate 6 to <12 YearsCohort 1: Comparator 6 to <12 YearsCohort 2: Tedizolid Phosphate 2 to <6 YearsCohort 2: Comparator 2 to <6 YearsCohort 3: Tedizolid Phosphate 28 Days to <2 YearsCohort 3: Comparator 28 Days to <2 Years
DiarrhoeaGastrointestinal disorders1/440/150/161/50/152/5
ConstipationGastrointestinal disorders0/440/150/161/50/150/5
FolliculitisInfections and infestations0/440/150/160/53/150/5
Upper respiratory tract infectionInfections and infestations0/440/150/161/52/150/5
Thermal burnInjury, poisoning and procedural complications0/440/150/161/50/150/5
Aspartate aminotransferase increasedInvestigations0/440/151/161/50/150/5
Decreased appetiteMetabolism and nutrition disorders0/440/150/161/51/151/5
AlopeciaSkin and subcutaneous tissue disorders0/440/150/161/50/150/5
Dermatitis diaperSkin and subcutaneous tissue disorders0/440/150/160/51/151/5
MiliariaSkin and subcutaneous tissue disorders0/440/150/160/50/151/5

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Cohort 1: Tedizolid Phosphate 6 to <12 YearsCohort 1: Comparator 6 to <12 YearsCohort 2: Tedizolid Phosphate 2 to <6 YearsCohort 2: Comparator 2 to <6 YearsCohort 3: Tedizolid Phosphate 28 Days to <2 YearsCohort 3: Comparator 28 Days to <2 YearsTotal
Mean8.5 ± 1.79.2 ± 1.43.1 ± 1.13.4 ± 1.10.9 ± 0.21.0 ± 0.16.0 ± 3.6
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Tedizolid Phosphate 6 to <12 YearsCohort 1: Comparator 6 to <12 YearsCohort 2: Tedizolid Phosphate 2 to <6 YearsCohort 2: Comparator 2 to <6 YearsCohort 3: Tedizolid Phosphate 28 Days to <2 YearsCohort 3: Comparator 28 Days to <2 YearsTotal
Female1688211247
Male287834353
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Tedizolid Phosphate 6 to <12 YearsCohort 1: Comparator 6 to <12 YearsCohort 2: Tedizolid Phosphate 2 to <6 YearsCohort 2: Comparator 2 to <6 YearsCohort 3: Tedizolid Phosphate 28 Days to <2 YearsCohort 3: Comparator 28 Days to <2 YearsTotal
Hispanic or Latino62512117
Not Hispanic or Latino381311413483
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Tedizolid Phosphate 6 to <12 YearsCohort 1: Comparator 6 to <12 YearsCohort 2: Tedizolid Phosphate 2 to <6 YearsCohort 2: Comparator 2 to <6 YearsCohort 3: Tedizolid Phosphate 28 Days to <2 YearsCohort 3: Comparator 28 Days to <2 YearsTotal
American Indian or Alaska Native0000101
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American00109111
White41151344380
More than one race3021118
Unknown or Not Reported0000000
08

Study locations

58 sites
  • Rady Children's Hospital-San Diego ( Site 0118)
    San Diego, California 92123, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago ( Site 0129)
    Chicago, Illinois 60611, United States
  • Children's Hospital of Michigan ( Site 0100)
    Detroit, Michigan 48201, United States
  • William Beaumont Hospital ( Site 0108)
    Royal Oak, Michigan 48073, United States
  • St. Louis Children's Hospital ( Site 0127)
    St Louis, Missouri 63110, United States
  • Cook Children's Medical Center ( Site 0124)
    Fort Worth, Texas 76104, United States
  • Baylor College of Medicine - Texas Children's Hospital ( Site 0107)
    Houston, Texas 77030, United States
  • Children's Hospital of Richmond at VCU ( Site 0123)
    Richmond, Virginia 23219, United States
  • Hospital Pequeno Principe ( Site 0276)
    Curitiba, Paraná 80250-060, Brazil
  • Inst de Medicina Integral Professor Fernando Figueira- IMIP ( Site 0277)
    Recife, Pernambuco 50070-902, Brazil
  • Centro de Estudos e Pesquisa em Molestias Infecciosas - CPCL-CENTRO DE ESTUDOS E PESQUISAS EM MOLES
    Natal, Rio Grande do Norte 59025-050, Brazil
  • Instituto D'Or de Pesquisa e Ensino (IDOR)-Hospital São Luiz Jabaquara ( Site 0283)
    São Paulo, 04321-120, Brazil
  • MHAT Sv. Nikolay Chudotvorets EOOD ( Site 0338)
    Lom, Montana 3600, Bulgaria
  • UMHAT Deva Maria ( Site 0333)
    Burgas, 8127, Bulgaria
  • MHAT City Clinic Sv. Georgi EOOD ( Site 0334)
    Montana, 3400, Bulgaria
  • MHAT Dr. Stamen Iliev AD ( Site 0339)
    Montana, 3400, Bulgaria
  • UMHAT Dr. Georgi Stranski EAD ( Site 0330)
    Pleven, 5800, Bulgaria
  • UMHAT Sv. Georgi ( Site 0332)
    Plovdiv, 4002, Bulgaria
  • MBAL Medica Ruse EOOD ( Site 0336)
    Rousse, 7000, Bulgaria
  • UMHAT Kanev AD ( Site 0337)
    Rousse, 7002, Bulgaria
  • UMHATEM. N.I.Pirogov. EAD ( Site 0331)
    Sofia, 1606, Bulgaria
  • JSC Evex Hospitals. ( Site 0601)
    Batumi, Adjara 6010, Georgia
  • Tbilisi State Medical University G. Zhvania Pediatric Academic Clinic ( Site 0600)
    Tbilisi, K'alak'i T'bilisi 0159, Georgia
  • JSC Evex Hospital ( Site 0602)
    Tbilisi, 0159, Georgia
  • JSC Evex Hospitals ( Site 0603)
    Tbilisi, 0159, Georgia
  • Haunersches Kinderspital ( Site 0480)
    München, Bavaria 80337, Germany
  • Clinica Privada ( Site 0551)
    Guatemala City, 01001, Guatemala
  • Private Practice Mario Melgar ( Site 0552)
    Guatemala City, 01009, Guatemala
  • Private Practice Dra. Manrique ( Site 0553)
    Guatemala City, 01010, Guatemala
  • Daugavpils Regional Hospital ( Site 0651)
    Daugavpils, 5417, Latvia
  • Liepaja Regional Hospital ( Site 0652)
    Liepāja, 3414, Latvia
  • Hospital of Lithuanian University of Health Sciences Kaunas ( Site 0701)
    Kaunas, 50161, Lithuania
  • Klaipedos Vaiku Ligonine ( Site 0700)
    Klaipėda, 92140, Lithuania
  • Vaiku ligonine VsI VUL Santaros kliniku filialas ( Site 0702)
    Vilnius, 08406, Lithuania
  • Hospital Civil Fray Antonio Alcalde-pediatrics infectious diseases ( Site 0230)
    Guadalajara, Jalisco 44280, Mexico
  • Instituto Nacional de Pediatria ( Site 0231)
    Mexico City, Mexico City 04530, Mexico
  • Hospital Infantil de Mexico Federico Gomez ( Site 0227)
    Mexico City, Mexico City 06720, Mexico
  • CHRISTUS - LATAM HUB CENTER OF EXCELLENCE AND INNOVATION S.C. ( Site 0241)
    General Escobedo, Nuevo León 64060, Mexico
  • Centenario Hospital Miguel Hidalgo-Pediatrics Department ( Site 0239)
    Aguascalientes, 20259, Mexico
  • Wojewodzki Szpital Obserwacyjno Zakazny ( Site 0429)
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-030, Poland
  • SZPZOZ im. Dzieci Warszawy w Dziekanowie Lesnym ( Site 0431)
    Łomianki, Masovian Voivodeship 05-092, Poland
  • Wojewodzki Szpital Specjalistyczny im. dr. Wladyslawa Bieganskiego ( Site 0427)
    Lodz, Łódź Voivodeship 91-347, Poland
  • City Childrens Clinical Emergency Hospital ( Site 0507)
    Novosibirsk, Novosibirsk Oblast 630007, Russia
  • Smolensk Regional Clinical Hospital ( Site 0511)
    Smolensk, Smolensk Oblast 214018, Russia
  • Children s Republican Clinical Hospital ( Site 0512)
    Kazan', Tatarstan, Respublika 420138, Russia
  • Emmed Research Incorporating ( Site 0377)
    Pretoria, Gauteng 0084, South Africa
  • Setshaba Research Centre ( Site 0378)
    Pretoria, Gauteng 0152, South Africa
  • Enhancing Care Foundation-DICRS ( Site 0381)
    Durban, KwaZulu-Natal 4013, South Africa
  • Cukurova Uni Tip Fak Cocuk Saglıgı ve Hasta ABD ( Site 0353)
    Adana, 01330, Turkey (Türkiye)
  • Hacettepe Universitesi Tip Fakultesi Hastanesi ( Site 0351)
    Ankara, 06230, Turkey (Türkiye)
  • Ankara City Hospital-Infectious Disease and Clinical Microbiology ( Site 0359)
    Ankara, 06800, Turkey (Türkiye)
  • Osmangazi UTF ( Site 0357)
    Eskişehir, 26480, Turkey (Türkiye)
  • Istanbul Universitesi Istanbul Tip Fakultesi ( Site 0355)
    Istanbul, 34093, Turkey (Türkiye)
  • Sisli Hamide Etfal Egitim ve Arastirma Hastanesi ( Site 0358)
    Istanbul, 34371, Turkey (Türkiye)
  • Ege UTF ( Site 0356)
    Izmir, 35040, Turkey (Türkiye)
  • Dnipropetrovsk Oblast Children's Clinical Hospital ( Site 0868)
    Dnipro, Dnipropetrovsk Oblast 49100, Ukraine
  • SI Dnipropetrovsk Regional Children Clinical Hospital DOR ( Site 0863)
    Dnipro, Dnipropetrovsk Oblast 49100, Ukraine
  • Ivano-Frankivsk Regional Children Clinical Hospital ( Site 0865)
    Ivano-Frankivsk, Ivano-Frankivsk Oblast 76014, Ukraine
09

References and documents

Publications

  • Mngqibisa R, Fofanov O, Grazioso CF, Melgar Toledo M, Boddicker M, Broyde N, Koseoglu S, Romero L, Stevens M, Sears P. A Phase 3 Study of the Safety and Efficacy of Tedizolid Phosphate in Patients <12 Years of Age With Acute Bacterial Skin and Skin Structure Infections. Pediatr Infect Dis J. 2025 Jun 1;44(6):533-538. doi: 10.1097/INF.0000000000004807. Epub 2025 Apr 14. PubMed 40233296 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Jul 2023, 53 months.

Results were first posted in Jul 2024, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2017
First posted
Jun 5, 2017
StartActual
Jan 20, 2019
Primary completionActual
Jul 6, 2023
CompletionActual
Jul 6, 2023
Results first posted
Jul 3, 2024
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03176134
Responsible party
Sponsor
First posted
Jun 5, 2017
Start date
Jan 20, 2019
Primary completion
Jul 6, 2023
Completion
Jul 6, 2023
Results posted
Jul 3, 2024
Last update
Jul 31, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tedizolid phosphate

Start the discussion